Pharma: Started Selling Generic Drugs Manufactured in Medreich on Schedule in Japan

Meiji Holdings Co., Ltd. Financial Results - For the First Half of FYE March 2018 -

	TOP

	Financial Results - For the First Half of FYE March 2018 -

	Contents

	1. Overview for the First Half

	2. Outlook for the Second Half and Full-year Summary - FYE March 2018 Use of Cash Flows Food: Grow in Sales of Domestic Core Products and International Business, and Reduce Cost Food: Steadily Grow Sales of Probiotics and Yogurt Food: Continue Sales Growth of Chocolate - Health and Premium Food: Bean to Bar - Meiji's strength Food: Change the Packaging for Drinking Milk Food: Business in China - Realize Solid Growth with Profit Increase Food: Establish Integrated R&D System and Create Unique Values Pharma: Steady Sales Growth and Further Low-Cost Operation Pharma: Steady Sales Growth Focusing Mainstay Brand-name Drugs and Generic Drugs in Japan (1) Pharma: Steady Sales Growth Focusing Mainstay Brand-name Drugs and Generic Drugs in Japan (2) Pharma: Started Selling Generic Drugs Manufactured in Medreich on Schedule in Japan Pharma: Establish Quality Control System Comply with Japanese GMP

	Appendix

	Back cover

Pharma: Started Selling Generic Drugs Manufactured in Medreich on Schedule in Japan

Prev. Page

Next Page

Download the PDF

Medreich
Established production system in India to manufacture high quality drugs for Japanese market. Launched on schedule in Japan

• Production plant for the Japanese market following Indonesia and Thailand

◾ Began manufacturing 4 products

◾ Launched in October

• Has production capacity for 3 billion tablets/year for the Japanese market

◾ Low cost manufacturing - cost reduction for Meiji Seika Pharma

◾ B to B transaction (CMO*) with Japanese generic drug companies

* CMO: Contract Manufacturing Organization